S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Ironwood Pharmaceuticals Stock Forecast, Price & News

-0.13 (-1.17%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.93 million shs
Average Volume
2.15 million shs
Market Capitalization
$1.80 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive IRWD News and Ratings via Email

Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Ironwood Pharmaceuticals logo

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc. is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, leveraging demonstrated expertise and capabilities in GI diseases. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.


Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap Down to $12.69
November 11, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$389.52 million
Cash Flow
$0.81 per share
Book Value
$3.54 per share


Net Income
$106.18 million
Pretax Margin




Free Float
Market Cap
$1.80 billion

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.28 out of 5 stars

Medical Sector

312th out of 1,388 stocks

Pharmaceutical Preparations Industry

135th out of 668 stocks

Analyst Opinion: 3.3Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -

Ironwood Pharmaceuticals (NASDAQ:IRWD) Frequently Asked Questions

Is Ironwood Pharmaceuticals a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Ironwood Pharmaceuticals stock.
View analyst ratings for Ironwood Pharmaceuticals
or view top-rated stocks.

How has Ironwood Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Ironwood Pharmaceuticals' stock was trading at $10.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IRWD stock has increased by 4.6% and is now trading at $10.98.
View which stocks have been most impacted by COVID-19

When is Ironwood Pharmaceuticals' next earnings date?

Ironwood Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, February 16th 2022.
View our earnings forecast for Ironwood Pharmaceuticals

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported $0.33 EPS for the quarter, beating analysts' consensus estimates of $0.31 by $0.02. The biotechnology company earned $103.75 million during the quarter, compared to analysts' expectations of $105.27 million. Ironwood Pharmaceuticals had a trailing twelve-month return on equity of 64.78% and a net margin of 128.30%. The firm's revenue for the quarter was up .3% on a year-over-year basis. During the same quarter last year, the firm earned $0.23 EPS.
View Ironwood Pharmaceuticals' earnings history

What guidance has Ironwood Pharmaceuticals issued on next quarter's earnings?

Ironwood Pharmaceuticals updated its FY 2021 earnings guidance on Thursday, November, 18th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $390 million-$410 million, compared to the consensus revenue estimate of $408.05 million.

What price target have analysts set for IRWD?

2 equities research analysts have issued 12-month price targets for Ironwood Pharmaceuticals' shares. Their forecasts range from $14.00 to $15.00. On average, they anticipate Ironwood Pharmaceuticals' share price to reach $14.50 in the next twelve months. This suggests a possible upside of 32.1% from the stock's current price.
View analysts' price targets for Ironwood Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Ironwood Pharmaceuticals' key executives?

Ironwood Pharmaceuticals' management team includes the following people:

What is Mark Mallon's approval rating as Ironwood Pharmaceuticals' CEO?

7 employees have rated Ironwood Pharmaceuticals CEO Mark Mallon on Glassdoor.com. Mark Mallon has an approval rating of 93% among Ironwood Pharmaceuticals' employees. This puts Mark Mallon in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Ironwood Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Micron Technology (MU) and Starbucks (SBUX).

What is Ironwood Pharmaceuticals' stock symbol?

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Who are Ironwood Pharmaceuticals' major shareholders?

Ironwood Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.66%), LSV Asset Management (4.80%), Camber Capital Management LP (3.38%), Credit Suisse AG (2.86%), Dimensional Fund Advisors LP (1.82%) and Geode Capital Management LLC (1.73%). Company insiders that own Ironwood Pharmaceuticals stock include Alexander J Denner, Jason Rickard, Julie Mchugh, Kelly Macdonald, Mark G Currie, Michael Shetzline, Ronald Silver, Thomas A Mccourt, Thomas A Mccourt and Timothy M O'reilly.
View institutional ownership trends for Ironwood Pharmaceuticals

Which institutional investors are selling Ironwood Pharmaceuticals stock?

IRWD stock was sold by a variety of institutional investors in the last quarter, including Camber Capital Management LP, Renaissance Technologies LLC, Bridger Management LLC, HealthInvest Partners AB, New York State Common Retirement Fund, Islet Management LP, AXA S.A., and Millennium Management LLC. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Jason Rickard, Mark G Currie, Michael Shetzline, Ronald Silver, and Thomas A Mccourt.
View insider buying and selling activity for Ironwood Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Ironwood Pharmaceuticals stock?

IRWD stock was bought by a variety of institutional investors in the last quarter, including LSV Asset Management, Skandinaviska Enskilda Banken AB publ , BlackRock Inc., Foundry Partners LLC, Arrowstreet Capital Limited Partnership, Credit Suisse AG, Two Sigma Advisers LP, and Squarepoint Ops LLC. Company insiders that have bought Ironwood Pharmaceuticals stock in the last two years include Alexander J Denner, and Timothy M O'reilly.
View insider buying and selling activity for Ironwood Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Ironwood Pharmaceuticals?

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ironwood Pharmaceuticals' stock price today?

One share of IRWD stock can currently be purchased for approximately $10.98.

How much money does Ironwood Pharmaceuticals make?

Ironwood Pharmaceuticals has a market capitalization of $1.80 billion and generates $389.52 million in revenue each year. The biotechnology company earns $106.18 million in net income (profit) each year or $3.25 on an earnings per share basis.

How many employees does Ironwood Pharmaceuticals have?

Ironwood Pharmaceuticals employs 232 workers across the globe.

What is Ironwood Pharmaceuticals' official website?

The official website for Ironwood Pharmaceuticals is www.ironwoodpharma.com.

Where are Ironwood Pharmaceuticals' headquarters?

Ironwood Pharmaceuticals is headquartered at 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110.

How can I contact Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals' mailing address is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. The biotechnology company can be reached via phone at (617) 621-7722, via email at [email protected], or via fax at 617-494-0480.

This page was last updated on 12/5/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.